These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
241 related items for PubMed ID: 9607845
1. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide. Lendvai N, Casadevall A, Liang Z, Goldman DL, Mukherjee J, Zuckier L. J Infect Dis; 1998 Jun; 177(6):1647-59. PubMed ID: 9607845 [Abstract] [Full Text] [Related]
2. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. Casadevall A, Mukherjee J, Devi SJ, Schneerson R, Robbins JB, Scharff MD. J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327 [Abstract] [Full Text] [Related]
3. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine. Pirofski L, Lui R, DeShaw M, Kressel AB, Zhong Z. Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223 [Abstract] [Full Text] [Related]
4. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen. Martinez LR, Moussai D, Casadevall A. Infect Immun; 2004 Jun; 72(6):3674-9. PubMed ID: 15155683 [Abstract] [Full Text] [Related]
14. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody. Zhang H, Zhong Z, Pirofski LA. Infect Immun; 1997 Apr; 65(4):1158-64. PubMed ID: 9119446 [Abstract] [Full Text] [Related]
15. In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages. Grinsell M, Weinhold LC, Cutler JE, Han Y, Kozel TR. J Infect Dis; 2001 Aug 15; 184(4):479-87. PubMed ID: 11471106 [Abstract] [Full Text] [Related]
16. Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates: implications for vaccine development. May RJ, Beenhouwer DO, Scharff MD. J Immunol; 2003 Nov 01; 171(9):4905-12. PubMed ID: 14568972 [Abstract] [Full Text] [Related]
17. A Glucuronoxylomannan Epitope Exhibits Serotype-Specific Accessibility and Redistributes towards the Capsule Surface during Titanization of the Fungal Pathogen Cryptococcus neoformans. Probert M, Zhou X, Goodall M, Johnston SA, Bielska E, Ballou ER, May RC. Infect Immun; 2019 Apr 01; 87(4):. PubMed ID: 30670549 [Abstract] [Full Text] [Related]
18. Mechanism of action of antibody to capsular polysaccharide in Cryptococcus neoformans infection. Feldmesser M, Casadevall A. Front Biosci; 1998 Feb 01; 3():d136-51. PubMed ID: 9445465 [Abstract] [Full Text] [Related]
19. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Mukherjee S, Lee S, Mukherjee J, Scharff MD, Casadevall A. Infect Immun; 1994 Mar 01; 62(3):1079-88. PubMed ID: 8112842 [Abstract] [Full Text] [Related]
20. Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Goldman DL, Lee SC, Casadevall A. Infect Immun; 1995 Sep 01; 63(9):3448-53. PubMed ID: 7642276 [Abstract] [Full Text] [Related] Page: [Next] [New Search]